PREVALENCE OF HELICOBACTER-PYLORI IN PEPTIC-ULCER PATIENTS IN GREATERROCHESTER, NY - IS EMPIRICAL TRIPLE THERAPY JUSTIFIED

Citation
S. Jyotheeswaran et al., PREVALENCE OF HELICOBACTER-PYLORI IN PEPTIC-ULCER PATIENTS IN GREATERROCHESTER, NY - IS EMPIRICAL TRIPLE THERAPY JUSTIFIED, The American journal of gastroenterology, 93(4), 1998, pp. 574-578
Citations number
13
Categorie Soggetti
Gastroenterology & Hepatology
ISSN journal
00029270
Volume
93
Issue
4
Year of publication
1998
Pages
574 - 578
Database
ISI
SICI code
0002-9270(1998)93:4<574:POHIPP>2.0.ZU;2-N
Abstract
Objectives: Among patients with peptic ulcer disease, the prevalence o f Helicobacter pylori has been reported to range from 80% to 90%,Thus empirical cost-effective therapy has been suggested. We surveyed patie nts with peptic ulcer disease in Rochester, NY. Methods: From two teac hing hospitals all patients who had duodenal ulcers (DU) and/or gastri c ulcers (GU) on esophagogastroduodenoscopy (EGD) with antral biopsy f or histology for H. pylori and for rapid urease (CLO) test were includ ed in the study. We examined a total of 160 patients with DU and 145 p atients with GU, age range 18-92 yr, obtaining clinical data, race, me dication profile, and history of use of nonsteroidal antiinflammatory drugs (NSAIDs). An ulcer was defined if the lesion with loss of mucosa l integrity was greater than or equal to 0.5 cm, with apparent depth. H. pylori was considered present if CLO test and/or histology were pos itive for H. pylori. To confirm the reliability of nonuse of NSAIDs, w e randomly checked blood samples of 90 such patients from the ambulato ry clinic for the presence of salicylates. To identify the sensitivity of the CLO test, we performed a serology test for H. pylori antibody in 100 subjects to compare the CLO test results. Also, 500 CLO test re sults were compared to the histology results for H. pylori. Results: A mong 160 DU patients, 16 were NSAID users with negative H. pylori and excluded from the prevalence study. Of the remaining 144 patients with DU, H. pylori was present in 88 patients (61%). When these data were analyzed according to race, H. pylori was present in 54 (52%) of 104 w hites compared to 34 of 40 (85%) nonwhites (blacks, Hispanics, Asians) (p < 0.01). Among 145 GU patients 18 were NSAID users with negative H . pylori and excluded from the prevalence analysis. Of the remaining 1 27 patients with GU, H. pylori was present in 87 patients (61%). Among them, H. pylori was present in 46 of 87 (53 %) whites, whereas 31 of 40 nonwhites (78 %) were H. pylori-positive (p < 0.01). Antral histolo gy and CLO test for R. pylori were in agreement in 92% of cases. Serol ogy and CLO test for H. pylori were in agreement in 87% of cases. None of the randomly screened patients, including 16 ulcer patients with n egative H; pylori, showed presence of salicylate in blood. Conclusion: In greater Rochester, NY, where the majority of our patients with EGD were whites, the prevalence of H. pylori among ulcer patients was low er compared to other regions, particularly among whites. This suggests that an additional causative factor or factors for peptic ulcers may be present. Hence, empirical antibiotic therapy of ulcer patients with out confirming the presence of H. pylori may not be justified. (C) 199 8 by Am. Coll. of Gastroenterology.